Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Louisiana Lomitapide Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedBlue Cross and Blue Shield of LouisianaPolicy 00243

    Lomitapide (Juxtapid) Coverage for Homozygous Familial Hypercholesterolemia

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy 00243 alerts

    Get alerted when Policy 00243 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage of lomitapide (Juxtapid) for eligible members with homozygous familial hypercholesterolemia, including initial therapy and reauthorization. Coverage requires available benefits, medical necessity, and satisfaction of the stated patient-selection criteria.

    Policy Summary
    PayerBlue Cross and Blue Shield of Louisiana
    PolicyLomitapide (Juxtapid) coverage for HoFH
    Policy CodePolicy 00243
    Change TypeModified
    Effective DateJan 1, 202743d
    Last ReviewOct 1, 2026
    Next Review DateOct 1, 2027
    Key ActionSubmit prior authorization documentation establishing age eligibility, HoFH diagnosis, prerequisite lipid-lowering therapy, and applicable LDL-C results.
    SourceLink
    POLICY UPDATE CHANGES

    Lomitapide coverage was revised to include patients 2 years of age and older with homozygous familial hypercholesterolemia.

    Patient-selection criteria were revised to require adherence to prerequisite lipid-lowering therapy and risk-based LDL-C thresholds.

    HoFH diagnostic criteria were clarified.

    Statin-intolerance definitions and prerequisite-therapy exceptions were updated.

    Reauthorization criteria for continued lomitapide therapy were added.

    The policy clarified that Juxtapid should not be used with Kynamro, PCSK9 inhibitors, or ATP citrate lyase inhibitors.

    ≥2 yearsMinimum eligible age
    12 weeksRequired prerequisite therapy duration
    >400 mg/dLUntreated LDL-C diagnostic pathway
    ≥300 mg/dLTreated LDL-C diagnostic pathway
    ≥55 or ≥70 mg/dLResidual LDL-C threshold
    AddedContinuation criteria

    Coverage Criteria

    Initial Therapy Criteria

    Initial coverage is considered when ALL of the following criteria are met.

    Initial therapy

    • Basic eligibility

      • The patient is at least 2 years of age and is adherent to medications required before authorization for lomitapide.Age ≥2 years
    • Required background therapy

      • Lomitapide will be used with a maximally tolerated statin in patients who are not statin intolerant, a maximally dosed PCSK9 inhibitor, and generic ezetimibe 10 mg daily.

        The PCSK9 inhibitor requirement does not apply when the patient has two LDL-receptor-negative alleles.

    • Clinical HoFH diagnosis

      • Genetic confirmation

        • Two mutant alleles are genetically confirmed at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus.Two mutant alleles
      • Untreated LDL-C pathway

        • Untreated LDL-C is greater than 400 mg/dL and the patient has either clinical manifestations of HoFH before age 10 or both parents with untreated LDL-C or total cholesterol levels consistent with HeFH.Untreated LDL-C >400 mg/dL

          Clinical manifestations include cutaneous or tendon xanthomas, arcus cornea, tuberous xanthomas, or xanthelasma.

        • Supporting finding

          • Clinical manifestations of HoFH occurred before age 10, or both parents had untreated lipid levels consistent with HeFH.Parent example: LDL-C ≥190 mg/dL and/or total cholesterol >250 mg/dL
      • Treated LDL-C pathway

        • Treated LDL-C is at least 300 mg/dL and the patient has either clinical manifestations of HoFH before age 10 or both parents with untreated LDL-C or total cholesterol levels consistent with HeFH.Treated LDL-C ≥300 mg/dL

          Treated LDL-C is measured after therapy with at least one antihyperlipidemic agent.

        • Supporting finding

          • Clinical manifestations of HoFH occurred before age 10, or both parents had untreated lipid levels consistent with HeFH.Parent example: LDL-C ≥190 mg/dL and/or total cholesterol >250 mg/dL
    • Prerequisite therapy and LDL-C response

      • Standard statin and ezetimibe pathway

        • The patient has tried a high-intensity statin at the maximum daily dose for at least 12 continuous weeks, or a maximally tolerated stable daily statin dose for at least 12 continuous weeks when maximum-dose high-intensity therapy was not well tolerated; has taken generic ezetimibe 10 mg daily with the statin for at least 12 continuous weeks; and has residual LDL-C at or above the applicable risk-based threshold.Atorvastatin ≥80 mg/day or rosuvastatin ≥40 mg/day; therapy ≥12 continuous weeks; LDL-C ≥70 mg/dL for high risk or ≥55 mg/dL for very high risk
      • Statin-intolerance pathway

        • The patient has residual LDL-C at or above the applicable risk-based threshold due to statin intolerance, has taken generic ezetimibe 10 mg daily without a statin for at least 12 continuous weeks, and meets the statin-intolerance requirements.LDL-C ≥70 mg/dL for high risk or ≥55 mg/dL for very high risk
        • Statin intolerance requirements

          • The patient was unable to tolerate at least two different statins, or one statin if rhabdomyolysis or clinically significant myonecrosis occurred; the adverse effects were confirmed and intolerable statin-related myopathy or myalgia; and symptoms or biomarker changes resolved or significantly improved after dose reduction or discontinuation.CK ≥10 times the upper limit of normal

            The one-statin exception applies to qualifying rhabdomyolysis or clinically significant myonecrosis.

    • PCSK9 inhibitor requirement or exception

      • PCSK9 inhibitor trial

        • The patient has tried a PCSK9 inhibitor for at least 12 continuous weeks at the FDA-approved maximum dose for HoFH and residual LDL-C remains at or above the applicable threshold.Evolocumab 420 mg every 2 weeks or alirocumab 150 mg every 2 weeks; therapy ≥12 continuous weeks; LDL-C ≥70 mg/dL for high risk or ≥55 mg/dL for very high risk
      • LDL-receptor genotype exception

        • The patient is known to have two LDL-receptor-negative alleles.Two negative alleles
      • Young pediatric exception

        • The patient is 2 to 9 years of age.Age 2–9 years

    Re-authorization Criteria

    Re-authorization requires ALL of the following.

    Continuation therapy

    • The patient previously met the initial criteria and received approval for lomitapide.

      Prior approval must be documented.

    • The patient has achieved clinically significant LDL-C lowering and remains adherent to lomitapide.Clinically significant LDL-C lowering

    Investigational or experimental use is excluded from coverage, including any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study.

    Juxtapid should not be used with Kynamro or PCSK9 inhibitors.

    Juxtapid should not be used in combination with ATP citrate lyase (ACL) inhibitors.

    Use is considered not medically necessary when required prerequisite medications have not been tried for at least 12 continuous weeks, when re-authorization criteria are not met, or when the patient is not adherent to the cholesterol-lowering regimen.

    Clinical Thresholds and Operational Values

    Minimum age
    Minimum eligible ageAt least 2 years of age
    PopulationAdults and pediatric patients
    Authorization requirementPatient must meet the age criterion before lomitapide authorization
    Untreated LDL-C HoFH pathway
    Untreated LDL-C threshold>400 mg/dL
    Measurement statusMeasured before therapy with any antihyperlipidemic agent
    Additional findingClinical HoFH manifestations before age 10 or both parents with lipid levels consistent with HeFH
    Treated LDL-C HoFH pathway
    Treated LDL-C thresholdAt least 300 mg/dL
    Measurement statusMeasured after therapy with at least one antihyperlipidemic agent
    Additional findingClinical HoFH manifestations before age 10 or both parents with lipid levels consistent with HeFH
    Both parents’ untreated LDL-C example
    Family-history requirementBoth parents had untreated lipid levels consistent with HeFH
    Untreated parental LDL-C exampleAt least 190 mg/dL in both parents
    Alternative parental measureUntreated total cholesterol greater than 250 mg/dL in both parents
    Both parents’ untreated total cholesterol example
    Family-history requirementBoth parents had untreated lipid levels consistent with HeFH
    Untreated parental total cholesterol example>250 mg/dL in both parents
    Alternative parental measureUntreated LDL-C at least 190 mg/dL in both parents
    Persistent LDL-C after prerequisite therapy
    High-risk thresholdLDL-C at least 70 mg/dL after prerequisite therapy
    Very-high-risk thresholdLDL-C at least 55 mg/dL after prerequisite therapy
    Applicable treatmentThreshold applies after the required statin, ezetimibe, or PCSK9 inhibitor regimen, as applicable
    Required therapy duration
    Required durationAt least 12 continuous weeks
    Therapies coveredStatin, generic ezetimibe 10 mg daily, and applicable PCSK9 inhibitor therapy
    Documentation consequenceThe 12-week requirement is an additional coverage requirement and may be denied as not medically necessary if not met
    Maximum high-intensity statin doses
    AtorvastatinAt least 80 mg daily
    RosuvastatinAt least 40 mg daily
    Treatment classificationHigh-intensity statin at the maximum daily dose
    Rhabdomyolysis or myonecrosis CK threshold
    Creatine kinase thresholdAt least 10 times the upper limit of normal
    Qualifying conditionRhabdomyolysis or clinically significant myonecrosis secondary to a statin
    One-statin exceptionInability to tolerate one statin may be accepted when this qualifying muscle injury occurred
    PCSK9 inhibitor HoFH maximum-dose examples
    Evolocumab maximum-dose example420 mg once every 2 weeks
    Alirocumab maximum-dose example150 mg once every 2 weeks
    Required trial durationAt least 12 continuous weeks at the FDA-approved maximum dose for HoFH
    Pediatric exception
    Exception age range2 to 9 years of age
    PCSK9 exceptionPatients in this age range may meet the PCSK9 inhibitor requirement through the pediatric exception
    Minimum age remainsThe patient must still be at least 2 years old

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required. Coverage may be considered only when benefits are available under the member’s contract and all medical-necessity and patient-selection requirements are met for lomitapide (Juxtapid) use in homozygous familial hypercholesterolemia (HoFH).

    • Patient is at least 2 years of age.
    • Patient is adherent to medications required before authorization.
    • Patient meets the required HoFH diagnostic pathway.
    • Required prerequisite lipid-lowering therapy, treatment durations, doses, and LDL-C response are documented.
    • Initial approval requires the applicable statin, ezetimibe, and PCSK9-inhibitor criteria, including statin-intolerance documentation when applicable.
    Prior Authorization

    Re-authorization Requirements

    Re-authorization requires documentation that the patient previously met the initial criteria and received approval for lomitapide, has achieved clinically significant LDL-C lowering, and remains adherent to lomitapide.

    • Re-authorization criteria are additional Company requirements.
    • Failure to meet continuation requirements may result in denial as not medically necessary.
    Step Therapy

    Required Lipid-Lowering Sequence

    Before lomitapide is authorized, document the required lipid-lowering sequence unless an exception applies. Use lomitapide with a maximally tolerated statin, maximally dosed PCSK9 inhibitor, and generic ezetimibe 10 mg daily when required.

    • The statin requirement does not apply when the patient is documented as statin intolerant.
    • The PCSK9-inhibitor requirement does not apply when the patient has two LDL-receptor-negative alleles or is 2–9 years of age under the applicable criterion.
    • Document the applicable exception and supporting clinical evidence.
    Documentation Required

    HoFH Diagnostic Evidence

    Submit clinical documentation establishing HoFH through at least one accepted pathway. The patient must meet the applicable genetic, untreated LDL-C, treated LDL-C, clinical-manifestation, or family-history requirements.

    • Genetic pathway: two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 locus.
    • Untreated pathway: LDL-C greater than 400 mg/dL plus clinical HoFH manifestations before age 10 or both parents with untreated values consistent with HeFH.
    • Treated pathway: LDL-C at least 300 mg/dL plus clinical HoFH manifestations before age 10 or both parents with untreated values consistent with HeFH.
    • Document relevant xanthomas, arcus cornea, xanthelasma, genetic results, untreated or treated LDL-C values, and parental lipid history.
    Documentation Required

    Prerequisite Medication History

    Document the patient’s complete prerequisite medication history before requesting lomitapide, including adherence, medication names, doses, treatment dates, and LDL-C results.

    • Record use of high-intensity or maximally tolerated statin therapy, generic ezetimibe 10 mg daily, and PCSK9-inhibitor therapy when applicable.
    • Document the FDA-approved maximum PCSK9-inhibitor dose used for HoFH.
    • If the patient is statin intolerant, document ezetimibe use without a statin and the qualifying intolerance evidence.
    Documentation Required

    Therapy Duration and LDL-C Results

    Coverage requires evidence that prerequisite therapy was used for at least 12 continuous weeks and that LDL-C remains above the applicable threshold after treatment.

    • High-intensity statin examples: atorvastatin at least 80 mg daily or rosuvastatin at least 40 mg daily, unless a maximally tolerated stable statin dose is supported by intolerance documentation.
    • Use statin plus ezetimibe for at least 12 continuous weeks; if statin intolerant, use ezetimibe alone for at least 12 continuous weeks.
    • Document post-treatment LDL-C of at least 70 mg/dL or at least 55 mg/dL according to the patient’s high-risk or very-high-risk classification.
    • For PCSK9 therapy, document at least 12 continuous weeks at the FDA-approved maximum HoFH dose and persistent LDL-C at or above the applicable threshold.
    Documentation Required

    Statin Intolerance Documentation

    When relying on statin intolerance, document the specific trials and adverse effects that satisfy the policy definition.

    • The patient must be unable to tolerate at least two different statins, unless one statin caused rhabdomyolysis or clinically significant myonecrosis.
    • Document confirmed intolerable statin-related myopathy or myalgia.
    • Document resolution or significant improvement of symptoms or biomarker abnormalities after dose reduction or discontinuation.
    • For rhabdomyolysis or myonecrosis, document muscle symptoms plus qualifying creatine kinase findings and acute renal failure or myoglobinuria when applicable.
    Prior Authorization

    Continuation Documentation

    For continuation requests, provide the prior lomitapide approval, evidence of clinically significant LDL-C lowering, and documentation that the patient remains adherent to lomitapide.

    • Continuation criteria must be met for re-authorization.
    • Failure to document clinically significant LDL-C lowering or adherence may result in denial as not medically necessary.
    Denial Risk

    Failure to Meet Coverage Criteria

    Coverage can be denied when benefits are unavailable, medical-necessity requirements are not met, or patient-selection criteria are not satisfied.

    • Lomitapide is eligible only when the member’s contract provides applicable benefits.
    • Patient-selection criteria must be met unless the policy specifically identifies the failure as not medically necessary.
    • Use that does not meet the applicable criteria may be treated as investigational.
    Denial Risk

    Insufficient Prerequisite Therapy

    Lomitapide is considered not medically necessary when the patient has not tried the required prerequisite medications for at least 12 weeks or the required treatment duration is not documented.

    • Document at least 12 continuous weeks of the required statin and ezetimibe regimen, or ezetimibe without a statin when statin intolerant.
    • Document at least 12 continuous weeks of maximum-dose PCSK9-inhibitor therapy when applicable.
    • Missing treatment dates, doses, adherence evidence, or persistent LDL-C results creates denial risk.
    Denial Risk

    Re-authorization Failure

    Re-authorization may be denied as not medically necessary when the patient did not previously meet initial criteria, did not receive prior approval, has not achieved clinically significant LDL-C lowering, or is not adherent to lomitapide.

    • Submit the prior approval and continuation clinical records with each re-authorization request.
    Denial Risk

    Nonadherence

    Lomitapide may be denied as not medically necessary when the patient is not adherent to the cholesterol-lowering regimen.

    • Document adherence to prerequisite lipid-lowering medications and lomitapide when requesting continuation.
    • Address gaps in therapy, missed doses, or other evidence of nonadherence before submitting the request.
    Denial Risk

    Investigational Use Not Covered

    Investigational or experimental medical treatments, drugs, devices, biological products, and treatment provided under the investigational arm of a clinical trial are not covered.

    • Use of lomitapide when patient-selection criteria are not met may be considered investigational, except where the policy expressly classifies the failure as not medically necessary.
    Denial Risk

    Avoid Prohibited Combination Therapy

    Do not use Juxtapid in combination with Kynamro or PCSK9 inhibitors. Confirm the patient’s complete medication list before authorization and during treatment.

    • Avoid combination with Kynamro (mipomersen).
    • Avoid combination with PCSK9 inhibitors such as Repatha (evolocumab) or Praluent (alirocumab).
    Denial Risk

    Combination With ACL Inhibitors

    Do not use Juxtapid in combination with ATP-citrate lyase (ACL) inhibitors. Review all lipid-lowering therapy before approval and document that prohibited combination therapy is not being used.

    • The policy prohibits combination use with the ACL-inhibitor class.
    • Resolve or document discontinuation of an ACL inhibitor before initiating or continuing Juxtapid.

    Therapeutic Background

    Lomitapide is an oral microsomal triglyceride transfer protein inhibitor used as an adjunct to a low-fat diet, exercise, and other LDL-C therapies for adults and pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia (HoFH). It reduces production of apolipoprotein B-containing lipoproteins and is intended to reduce LDL-C. Because lomitapide may cause hepatotoxicity and hepatic fat accumulation, liver-related laboratory testing is required before and during treatment, and the drug is available only through the Juxtapid REMS Program.

    Policy Definitions

    Homozygous familial hypercholesterolemia
    Genetic pathwayTwo mutant alleles are genetically confirmed at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus
    Untreated LDL-C pathwayUntreated LDL-C greater than 400 mg/dL plus qualifying clinical manifestations before age 10 or parental lipid levels consistent with HeFH
    Treated LDL-C pathwayTreated LDL-C at least 300 mg/dL plus qualifying clinical manifestations before age 10 or parental lipid levels consistent with HeFH
    Untreated LDL-C
    DefinitionThe period before therapy with any antihyperlipidemic agent
    Examples of therapy excluded from untreated statusStatins, ezetimibe, PCSK9 inhibitors, and other antihyperlipidemic agents
    Use in diagnosisUntreated status is used in the untreated LDL-C and parental lipid pathways
    Treated LDL-C
    DefinitionLDL-C measured after therapy with at least one antihyperlipidemic agent
    Examples of qualifying therapyStatins, ezetimibe, PCSK9 inhibitors, or evinacumab-dgnb
    Diagnostic thresholdThe treated HoFH pathway uses LDL-C of at least 300 mg/dL
    Statin intolerance
    Statin trialsUnable to tolerate at least two different statins
    One-statin exceptionOne statin is sufficient when rhabdomyolysis or clinically significant myonecrosis occurred
    Required clinical evidenceConfirmed intolerable statin-related muscle effects that resolve or significantly improve after dose reduction or discontinuation
    Clinical ASCVD
    Coronary diseaseMyocardial infarction, acute coronary syndrome, angina, or coronary revascularization
    Cerebrovascular diseaseTransient ischemic attack or ischemic stroke
    Peripheral or other atherosclerotic diseaseAtherosclerotic peripheral arterial disease or other documented atherosclerotic disease, including renal atherosclerosis, aortic aneurysm secondary to atherosclerosis, or carotid plaque
    ACL inhibitors
    Full termATP citrate lyase inhibitors
    Drug classA lipid-lowering drug class
    Combination restrictionJuxtapid should not be used in combination with ACL inhibitors
    Investigational
    Core definitionA treatment, procedure, drug, device, or biological product whose effectiveness has not been clearly tested and has not been incorporated into standard medical practice
    Regulatory considerationThe determination considers whether the product can be lawfully marketed and whether FDA approval has been granted
    Evidence considerationFurther studies may be needed to establish dose, toxicity, safety, effectiveness, comparative effectiveness, or improved health outcomes
    Medically Necessary
    Clinical purposeCare a prudent provider would provide to prevent, evaluate, diagnose, or treat illness, injury, disease, or symptoms
    Standard and effectiveness requirementsMust accord with nationally accepted standards and be clinically appropriate and effective for the patient’s condition
    ExclusionsMust not be primarily for convenience or more costly than an equally effective alternative

    Initial Therapy

    Continuation and Re-authorization

    Re-authorization Criteria

    Re-authorization requires ALL listed continuation criteria.

    Lomitapide continuation

    • The patient previously met the initial lomitapide criteria and received approval.

      Prior approval must be documented.

    • The patient has achieved clinically significant LDL-C lowering and remains adherent to lomitapide.Clinically significant LDL-C lowering

    Updated Continuation Therapy Criteria

    Continued therapy requires reauthorization under the updated policy criteria.

    Continuation therapy

    • The patient previously met the initial lomitapide criteria and received approval.

      Reauthorization is required for continued therapy.

    • The patient has achieved clinically significant LDL-C lowering.Clinically significant LDL-C lowering
    • The patient remains adherent to lomitapide.

      Failure to meet the continuation requirements may be considered not medically necessary.

    Required Precursor Therapy

    StepPrerequisite therapyRequirementException or result
    1High-intensity statin at the maximum daily dose, or a maximally tolerated stable daily statin dose when maximum-dose high-intensity therapy was not toleratedAt least 12 continuous weeksMaximum-dose examples: atorvastatin ≥80 mg daily or rosuvastatin ≥40 mg daily
    2Generic ezetimibe 10 mg daily with the statinAt least 12 continuous weeksFor statin intolerance, use generic ezetimibe 10 mg daily without a statin for at least 12 continuous weeks
    3PCSK9 inhibitor at the FDA-approved maximum dose for HoFHAt least 12 continuous weeksExamples: evolocumab 420 mg once every 2 weeks or alirocumab 150 mg once every 2 weeks; persistent LDL-C must remain ≥70 mg/dL for high-risk or ≥55 mg/dL for very-high-risk patients
    4LomitapideConsider after the required prerequisite therapyPCSK9 inhibitor therapy is not required when the patient has two LDL-receptor-negative alleles or is 2 to 9 years of age
    TherapyUpdated prerequisite requirementApplicable exception
    Maximally tolerated statinUse before or with lomitapide as part of prerequisite lipid-lowering therapyThe updated criteria address use of maximally tolerated statin therapy; statin-intolerant patients are subject to the stated exception
    EzetimibeUse before or with lomitapide as part of prerequisite lipid-lowering therapySubject to the updated patient-selection criteria
    PCSK9 inhibitorUse when appropriate before or with lomitapideNot required for patients with two LDL-receptor-negative alleles or patients 2 to 9 years of age
    Policy Summary
    PayerBlue Cross and Blue Shield of Louisiana
    PolicyLomitapide (Juxtapid) coverage for HoFH
    Policy CodePolicy 00243
    Change TypeModified
    Effective DateJan 1, 202743d
    Last ReviewOct 1, 2026
    Next Review DateOct 1, 2027
    Key ActionSubmit prior authorization documentation establishing age eligibility, HoFH diagnosis, prerequisite lipid-lowering therapy, and applicable LDL-C results.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Operational ValuesAuthorization and Documentation RequirementsTherapeutic BackgroundPolicy DefinitionsInitial TherapyContinuation and Re-authorizationRequired Precursor Therapy

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.